Sartorius Stedim Biotech SA 2021 IR
The report outlines Sartorius Stedim Biotech's financial and operational performance for the fiscal year 2021, highlighting a significant sales revenue increase of 53% to approximately 2.89 billion euros. This growth was driven by strong demand in the biopharmaceutical sector, particularly for coronavirus vaccine production, and supported by extensive capacity expansions and strategic acquisitions like CellGenix and Xell. The company also set an ambitious target to reduce its CO2 emission intensity by around 10% annually.
Company: Sartorius Stedim Biotech SA
Sector: Health Care
Country: France
Year: 2021
Type: IR
Pages: 271
Sartorius Stedim Biotech SA
Universal Registration Document
The report outlines Sartorius Stedim Biotech's financial and operational performance for the fiscal year 2021, highlighting a significant sales revenue increase of 53% to approximately 2.89 billion euros. This growth was driven by strong demand in the biopharmaceutical sector, particularly for coronavirus vaccine production, and supported by extensive capacity expansions and strategic acquisitions like CellGenix and Xell. The company also set an ambitious target to reduce its CO2 emission intensity by around 10% annually.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Published
Feb 16, 2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Employees